−2.90USD
−212.22 MUSD
9.56 MUSD
71.37 M
About Avidity Biosciences, Inc.
Sector
Industry
CEO
Sarah Boyce
Website
Headquarters
San Diego
Employees (FY)
253
Founded
2012
FIGI
BBG00FQ7LXW1
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RNA is 25.09 USD — it has decreased by 0.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Avidity Biosciences, Inc. stocks are traded under the ticker RNA.
Avidity Biosciences, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
RNA stock is 4.37% volatile and has beta coefficient of 2.28. Check out the list of the most volatile stocks — is Avidity Biosciences, Inc. there?
RNA earnings for the last quarter are −0.71 USD per share, whereas the estimation was −0.76 USD resulting in a 6.17% surprise. The estimated earnings for the next quarter are −0.66 USD per share. See more details about Avidity Biosciences, Inc. earnings.
Avidity Biosciences, Inc. revenue for the last quarter amounts to 2.82 M USD despite the estimated figure of 2.21 M USD. In the next quarter revenue is expected to reach 12.21 M USD.
Yes, you can track Avidity Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
RNA stock has risen by 3.59% compared to the previous week, the month change is a 6.18% rise, over the last year Avidity Biosciences, Inc. has showed a 48.90% increase.
RNA net income for the last quarter is −60.44 M USD, while the quarter before that showed −52.36 M USD of net income which accounts for −15.44% change. Track more Avidity Biosciences, Inc. financial stats to get the full picture.
Today Avidity Biosciences, Inc. has the market capitalization of 2.00 B, it has increased by 1.05% over the last week.
No, RNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Avidity Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 253.00 employees. See our rating of the largest employees — is Avidity Biosciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Avidity Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Avidity Biosciences, Inc. stock shows the buy signal. See more of Avidity Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Avidity Biosciences, Inc. future price: according to them, RNA price has a max estimate of 71.00 USD and a min estimate of 18.00 USD. Read a more detailed Avidity Biosciences, Inc. forecast: see what analysts think of Avidity Biosciences, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Avidity Biosciences, Inc. EBITDA is −231.34 M USD, and current EBITDA margin is −2.44 K%. See more stats in Avidity Biosciences, Inc. financial statements.